MyFinsight
Home
Blog
About
Aggregate gross proceeds
$1,988K
Represents proceeds from
issuance of ordinary...
$998K
(-69.54%↓ Y/Y)
Net cash provided by
(used in) financing...
$2,740K
(-62.14%↓ Y/Y)
Canceled cashflow
$246K
Cash, cash
equivalents, restricted...
-$186K
(-108.19%↓ Y/Y)
Canceled cashflow
$2,740K
Increase (decrease) in
accounts payable, trade
$268K
(213.08%↑ Y/Y)
Share-based payment
arrangement, noncash expense
$197K
(239.66%↑ Y/Y)
Decrease (increase) in
prepaid expenses
-$157K
(-121.90%↓ Y/Y)
Increase (decrease) in
other accounts...
$90K
(169.77%↑ Y/Y)
Increase (decrease) in
employee related...
$68K
(585.71%↑ Y/Y)
Depreciation
$3K
(-57.14%↓ Y/Y)
Issuance costs related to
warrants inducement...
$125K
(-72.94%↓ Y/Y)
Payment and prepayment
of issuance costs...
$121K
Net cash provided by
(used in) operating...
-$2,925K
(41.03%↑ Y/Y)
Canceled cashflow
$783K
Net cash provided by
(used in) investing...
-$1K
(85.71%↑ Y/Y)
Net loss
-$3,551K
(16.21%↑ Y/Y)
Non-cash financial
expenses
$135K
Increase in other current
assets
$15K
(1400.00%↑ Y/Y)
Increase (decrease) in
operating lease liability
-$7K
(-800.00%↓ Y/Y)
Investment in long-term
deposits
$1K
Back
Back
Cash Flow
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)
source: myfinsight.com